Editas Medicine Share Price (NASDAQ: EDIT)

$2.79

▲

0.06

(2.2%)

Last updated on August 23, 2025 at 1:29 AM IST

$₹

Check the interactive Editas Medicine Stock chart to analyse performance

Editas Medicine stock performance

as on August 23, 2025 at 1:29 AM IST

Today's Low:$2.75
Today's High:$2.92
$2.79
1.43%
Downside
Day's Volatility :5.82%
Upside
4.45%
52 Weeks Low:$0.91
52 Weeks High:$4.12
$2.79
67.38%
Downside
52 Weeks Volatility :77.91%
Upside
32.28%

Editas Medicine Stock Returns

Period	Editas Medicine Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	69.39%	6.0%	0.0%
6 Months	39.05%	-6.4%	0.0%
1 Year	-28.7%	-11.1%	0.0%
3 Years	-82.82%	6.7%	-8.6%

Editas Medicine Inc. Key Stats

Check Editas Medicine key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$2.73
Open	$2.75
Today's High	$2.92
Today's Low	$2.75
Market Capitalization	$245.5M
Today's Volume	$1.5M
52 Week High	$4.12
52 Week Low	$0.9101
Revenue TTM	$38.9M
EBITDA	$-154.1M
Earnings Per Share (EPS)	$-2.84
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-188.58%

Stock Returns calculator for Editas Medicine Stock including INR - Dollar returns

The Editas Medicine stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Editas Medicine investment value today

Current value as on today

₹75,489

Returns

₹24,511

(-24.51%)

Returns from Editas Medicine Stock

₹28,827 (-28.83%)

Dollar Returns*

₹4,316 (+4.32%)

Indian investors sentiment towards Editas Medicine Stock

Period: Jul 24, 2025 to Aug 23, 2025. Change in 30 Days versus previous period

Search interest for Editas Medicine Stock from India on INDmoney has increased by 4% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Editas Medicine Inc.

Name
Holdings %
Name
Holdings %
Vanguard Group Inc
8.19%
BlackRock Inc
7.66%
Morgan Stanley - Brokerage Accounts
3.04%
Geode Capital Management, LLC
2.22%
State Street Corp
2.11%
Bank of America Corp
1.74%

Analyst Recommendation on Editas Medicine Stock

Rating

Trend

Buy

54%Buy

41%Hold

4%Sell

Based on 24 Wall street analysts offering stock ratings for Editas Medicine(by analysts ranked 0 to 5 stars)

Editas Medicine Share Price Target

What analysts predicted

Upside of 38.89%

Target:

$3.88

Current:

$2.79

Editas Medicine share price target is $3.88, a slight Upside of 38.89% compared to current price of $2.79 as per analysts' prediction.

Editas Medicine Stock Insights

Price Movement
In the last 7 days, EDIT stock has moved down by -7.8%
Decreasing Revenue
Revenue is down for the last 3 quarters, 30.60M → 3.57M (in $), with an average decrease of 54.0% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -76.08M → -53.23M (in $), with an average increase of 42.9% per quarter
EDIT vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.6% return, outperforming this stock by 94.4%
EDIT vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 105.6% return, outperforming this stock by 188.2%
Price to Sales
ForEDIT every $1 of sales, investors are willing to pay $6.0, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.9 for every $1 of sales.

Editas Medicine Inc. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$20.5M	↓ 35.71%
Net Income	$-133.7M	↑ 21.64%
Net Profit Margin	-651.43%	↓ 307.15%

	FY20	Y/Y Change
Revenue	$90.7M	↑ 341.93%
Net Income	$-109.4M	↓ 18.19%
Net Profit Margin	-120.59%	↑ 530.84%

	FY21	Y/Y Change
Revenue	$25.5M	↓ 71.85%
Net Income	$-185.1M	↑ 69.18%
Net Profit Margin	-724.66%	↓ 604.07%

	FY22	Y/Y Change
Revenue	$19.7M	↓ 22.83%
Net Income	$-204.4M	↑ 10.4%
Net Profit Margin	-1.0K%	↓ 312.03%

	FY23	Y/Y Change
Revenue	$78.1M	↑ 296.32%
Net Income	$-153.2M	↓ 25.02%
Net Profit Margin	-196.13%	↑ 840.56%

	FY24	Y/Y Change
Revenue	$32.3M	↓ 58.64%
Net Income	$-237.1M	↑ 54.74%
Net Profit Margin	-733.72%	↓ 537.59%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$1.1M	↓ 98.11%
Net Income	$-62.0M	↑ 228.23%
Net Profit Margin	-5.5K%	↓ 5426.72%

	Q2 FY24	Q/Q Change
Revenue	$513.0K	↓ 54.8%
Net Income	$-67.6M	↑ 9.13%
Net Profit Margin	-13.2K%	↓ 7720.6%

	Q3 FY24	Q/Q Change
Revenue	$61.0K	↓ 88.11%
Net Income	$-62.1M	↓ 8.08%
Net Profit Margin	-101.9K%	↓ 88691.74%

	Q4 FY24	Q/Q Change
Revenue	$30.6M	↑ 50070.49%
Net Income	$-45.4M	↓ 26.95%
Net Profit Margin	-148.33%	↑ 101722.16%

	Q1 FY25	Q/Q Change
Revenue	$4.7M	↓ 84.78%
Net Income	$-76.1M	↑ 67.61%
Net Profit Margin	-1.6K%	↓ 1485.16%

	Q2 FY25	Q/Q Change
Revenue	$3.6M	↓ 23.19%
Net Income	$-53.2M	↓ 30.03%
Net Profit Margin	-1.5K%	↑ 145.65%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$-76.4M	↑ 30.06%

	FY20	Y/Y Change
Profit	$90.7M	↓ 218.81%

	FY21	Y/Y Change
Profit	$25.5M	↓ 71.85%

	FY22	Y/Y Change
Profit	$19.7M	↓ 22.83%

	FY23	Y/Y Change
Profit	$72.1M	↑ 265.56%

	FY24	Y/Y Change
Profit	$26.5M	↓ 63.22%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$-274.0K	↓ 100.47%

	Q2 FY24	Q/Q Change
Profit	$-907.0K	↑ 231.02%

	Q3 FY24	Q/Q Change
Profit	$-1.5M	↑ 69.57%

	Q4 FY24	Q/Q Change
Profit	$29.2M	↓ 2000.07%

	Q1 FY25	Q/Q Change
Profit	$4.7M	↓ 84.06%

	Q2 FY25	Q/Q Change
Profit	$3.6M	↓ 23.19%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-40.7M	↓ 11.02%
Investing Cash Flow	$12.3M	↓ 123.08%
Financing Cash Flow	$131.8M	↑ 51.63%

	FY20	Y/Y Change
Operating Cash Flow	$-179.8M	↑ 342.21%
Investing Cash Flow	$-140.5M	↓ 1246.93%
Financing Cash Flow	$224.1M	↑ 70.02%

	FY21	Y/Y Change
Operating Cash Flow	$-163.8M	↓ 8.92%
Investing Cash Flow	$-54.5M	↓ 61.24%
Financing Cash Flow	$282.1M	↑ 25.87%

	FY22	Y/Y Change
Operating Cash Flow	$-177.3M	↑ 8.27%
Investing Cash Flow	$114.1M	↓ 309.43%
Financing Cash Flow	$1.3M	↓ 99.54%

	FY23	Y/Y Change
Operating Cash Flow	$-132.2M	↓ 25.47%
Investing Cash Flow	$-3.7M	↓ 103.27%
Financing Cash Flow	$118.0M	↑ 9093.07%

	FY24	Y/Y Change
Operating Cash Flow	$-210.3M	↑ 59.09%
Investing Cash Flow	$162.1M	↓ 4445.91%
Financing Cash Flow	$56.0M	↓ 52.54%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-49.9M	↑ 124.24%
Investing Cash Flow	$-4.7M	↓ 107.55%
Financing Cash Flow	$192.0K	↓ 62.65%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-57.1M	↑ 14.42%
Investing Cash Flow	$52.0M	↓ 1194.92%
Financing Cash Flow	$322.0K	↑ 67.71%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-52.6M	↓ 7.84%
Investing Cash Flow	$84.0M	↑ 61.64%
Financing Cash Flow	$0.0	↓ 100.0%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-50.8M	↓ 3.47%
Investing Cash Flow	$31.0M	↓ 63.14%
Financing Cash Flow	$55.5M	-

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-47.8M	↓ 5.84%
Investing Cash Flow	$56.4M	↑ 82.14%
Financing Cash Flow	$-1.4M	↓ 102.59%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-50.2M	↑ 5.05%
Investing Cash Flow	$42.7M	↓ 24.36%
Financing Cash Flow	$7.4M	↓ 615.8%

Editas Medicine Technicals Summary

Sell

Neutral

Buy

Editas Medicine is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Editas Medicine Inc. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Editas Medicine Inc.	-11.27%	39.05%	-28.7%	-82.82%	-92.02%
Regeneron Pharmaceuticals, Inc.	4.66%	-17.37%	-50.86%	-2.39%	-3.46%
Beone Medicines Ltd	7.62%	21.35%	57.45%	78.28%	25.05%
Vertex Pharmaceuticals Incorporated	-15.87%	-17.97%	-18.14%	35.67%	45.07%
Alnylam Pharmaceuticals, Inc.	38.16%	82.49%	68.79%	112.36%	238.79%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Editas Medicine Inc.	NA	NA	0.0	-2.03	-1.89	-0.34	NA	0.22
Regeneron Pharmaceuticals, Inc.	15.08	15.08	1.23	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.29	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	28.25	28.25	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Editas Medicine Inc.	Buy	$245.5M	-92.02%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$63.4B	-3.46%	15.08	31.37%
Beone Medicines Ltd	NA	$38.2B	25.05%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$101.9B	45.07%	28.25	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$60.1B	238.79%	NA	-12.96%

About Editas Medicine Inc.

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Organization	Editas Medicine
Employees	246
CEO	Dr. Gilmore O'Neill M.D.
Industry	Health Technology

Key Management of Editas Medicine Inc.

Name	Title
Dr. Gilmore O'Neill M.D.	President, CEO & Director
Dr. Feng Zhang Ph.D.	Co-Founder & Scientific Advisory Board Member
Dr. George McDonald Church Ph.D.	Co-Founder & Scientific Advisory Board Member
Ms. Amy Parison	Senior VP & CFO
Mr. Gregory Whitehead	Executive VP and Chief Technical & Quality Officer
Dr. Linda C. Burkly Ph.D.	Executive VP & Chief Scientific Officer
Ms. Linea Aspesi	Executive VP & Chief Administration Officer
Cristi Barnett	Senior VP of Corporate Communications & Investor Relations
Mr. Damien Grierson J.D.	Senior VP, General Counsel & Corporate Secretary
Mr. Frank Panaccio	Senior VP & Chief Business Officer

Important FAQs about investing in EDIT Stock from India :

What is Editas Medicine share price today?

Editas Medicine share price today is $2.79 as on August 23, 2025 at 1:29 AM IST at the close of the market. Editas Medicine share today touched a day high of $2.92 and a low of $2.75.

What is the 52 week high and 52 week low for Editas Medicine share?

Editas Medicine share touched a 52 week high of $4.12 and a 52 week low of $0.91. Editas Medicine stock price today i.e. August 23, 2025 at 1:29 AM IST is closed at $2.79, lower by 32.28% versus the 52 week high.

How to invest in Editas Medicine Stock (EDIT) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Editas Medicine on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Editas Medicine Shares that will get you 0.5376 shares as per Editas Medicine share price of $2.79 per share as on August 23, 2025 at 1:29 AM IST.

What is the minimum amount required to buy Editas Medicine Stock (EDIT) from India?

Indian investors can start investing in Editas Medicine (EDIT) shares with as little as ₹87.521 or $1 (as of August 24, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹875.21 in Editas Medicine stock (as per the Rupee-Dollar exchange rate as on August 24, 2025). Based on Editas Medicine share’s latest price of $2.79 as on August 23, 2025 at 1:29 AM IST, you will get 3.5842 shares of Editas Medicine. Learn more about fractional shares .

What are the returns that Editas Medicine has given to Indian investors in the last 5 years?

Editas Medicine stock has given -92.02% share price returns and 18.0% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?